Physician Resources for Stem Cell Transplant and Cellular Therapies
We collaborate with referring providers to ensure that more patients can access the most advanced care and treatment available. Dana-Farber Brigham Cancer Center has a long history of utilizing cellular therapies to treat blood cancers and blood disorders. Over the course of 50 years, we have performed more than 11,600 hematopoietic stem cell transplants—the original form of cellular therapy. We continue to offer patients the latest treatments, including CAR T-cell therapy, other genetically-modified T cells, and cancer vaccines.
Through partnering with you, we can help your patients receive their care closer to home, reducing the time and cost of care without sacrificing quality. Learn more about our unique approach, and how to refer your patients to our Stem Cell Transplantation and Cellular Therapies programs:
Stem Cell Transplantation and Cellular Therapies Annual Symposium
This annual education program is for physicians, nurses, social workers, and payors who care for patients with cancer who may be appropriate for cellular therapy treatment. The symposium features presentations and panel discussions about the rapidly emerging and evolving cellular therapies, with insight on eligibility, referral guidelines, and post-treatment management. Information about the 2023 fall event will be posted this summer.
Celebrating 50 Years of Stem Cell Transplantation
Learn about the history, progress, and innovation in the adult stem cell transplantation program over the past 50 years.
Program Accreditations, Registrations, and Licenses
- Foundation for the Accreditation of Cellular Therapy (FACT)
- U.S. Food and Drug Administration
- American Association of Blood Banks (AABB)
- Centers for Medicare and Medicaid Services
- The Joint Commission
- National Marrow Donor Program (NMDP) – fully accredited
Clinical and Research Affiliations
- Member of the Center for International Blood and Marrow Transplant Research (CIBMTR)
- Charter member of the Blood and Marrow Transplant Clinical Trials Network of the National Institutes of Health (BMT-CTN)
- Member of the Alliance for Clinical Trials in Oncology (formerly CALGB)
- Founding member of Dana-Farber/Harvard Cancer Center, designated a comprehensive cancer center by the National Cancer Institute
Clinical Education Opportunities
We offer observerships for physicians, mid-level practitioners, and nurses to shadow clinicians in the Hematologic Malignancies and Stem Cell Transplant departments. While observerships are overseen organizationally by Dana-Farber, curricula and scheduling are managed directly by each department. For hematologic malignancy and stem cell transplant observerships, email katie_kupferberg@dfci.harvard.edu.
In addition, as a principal teaching affiliate of Harvard Medical School, we share advances in cancer research and treatment with the health care community through continuing medical education (CME) and continuing educational unit (CEU) courses. Learn more about education and training opportunities.
Subscribe to Advances in Hematologic Malignancies
This free biannual e-newsletter provides updates about Dana-Farber Brigham Cancer Center’s hematologic oncology research and care, current clinical trials, and upcoming CME programs.